ImmuCell (ICCC) plans a controlled launch of Re-Tain, a treatment for dairy cows with subclinical mastitis, which affects milk production.
"This investigational strategy allows us to collect product performance data" while the full non-administrative new animal drug application submission is in the final stages of review, the company said Wednesday in a statement.
Clearing inspectional observations at the contract manufacturer's facilities "is still the critical path constraint" for approval, the company said.
The test marketing isn't expected to generate significant revenue or profit, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。